CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 24, 2006--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX - News), a developer of innovative pharmaceuticals for magnetic resonance imaging (MRI), today announced that Michael Gilman, Ph.D. has been appointed to its Board of Directors. Dr. Gilman has been providing consulting services to EPIX since the third quarter of 2005, as the Company evaluated privately-held biotechnology companies for acquisition. On April 3, 2006, the Company announced the signing of a definitive merger agreement with Predix Pharmaceuticals, Inc., a privately-held pharmaceutical company based in Lexington, Massachusetts. Until November, 2005, Dr. Gilman was Executive Vice President, Research at Biogen IDEC, having joined that company in 1999 as Director of Molecular Biology.
